In last trading session, KalVista Pharmaceuticals Inc (NASDAQ:KALV) saw 0.42 million shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $7.85 trading at -$0.39 or -4.73% at ring of the bell on the day assigns it a market valuation of $387.93M. That closing price of KALV’s stock is at a discount of -115.03% from its 52-week high price of $16.88 and is indicating a discount of -1.53% from its 52-week low price of $7.97. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.19 million shares which gives us an average trading volume of 346.65K if we extend that period to 3-months.
For KalVista Pharmaceuticals Inc (KALV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.88 in the current quarter.
KalVista Pharmaceuticals Inc (NASDAQ:KALV) trade information
Upright in the red during last session for losing -4.73%, in the last five days KALV remained trading in the red while hitting it’s week-highest on Friday, 01/03/25 when the stock touched $7.85 price level, adding 14.21% to its value on the day. KalVista Pharmaceuticals Inc’s shares saw a change of -7.32% in year-to-date performance and have moved -11.40% in past 5-day. KalVista Pharmaceuticals Inc (NASDAQ:KALV) showed a performance of -15.95% in past 30-days. Number of shares sold short was 7.37 million shares which calculate 23.75 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 60.75% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would drop -154.78% in reaching the projected high whereas dropping to the targeted low would mean a loss of -154.78% for stock’s current value.
KalVista Pharmaceuticals Inc (KALV) estimates and forecasts
Statistics highlight that KalVista Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -37.20% of value to its shares in past 6 months, showing an annual growth rate of -3.49% while that of industry is 16.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -20.06% during past 5 years.
KalVista Pharmaceuticals Inc (NASDAQ:KALV)’s Major holders
Insiders are in possession of 1.36% of company’s total shares while institution are holding 110.29 percent of that, with stock having share float percentage of 111.80%. Investors also watch the number of corporate investors in a company very closely, which is 110.29% institutions for KalVista Pharmaceuticals Inc that are currently holding shares of the company. VR ADVISER, LLC is the top institutional holder at KALV for having 6.25 million shares of worth $73.62 million. And as of 2024-06-30, it was holding 14.3373 of the company’s outstanding shares.
The second largest institutional holder is TANG CAPITAL MANAGEMENT LLC, which was holding about 4.22 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6783 of outstanding shares, having a total worth of $49.7 million.
On the other hand, Smallcap World Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 3.37 shares of worth $26.49 million or 6.83% of the total outstanding shares. The later fund manager was in possession of 1.2 shares on Sep 30, 2024 , making its stake of worth around $9.42 million in the company or a holder of 2.43% of company’s stock.
